痫愈胶囊联合左乙拉西坦治疗癫痫的临床研究
|
摘要
目的探讨痫愈胶囊联合左乙拉西坦片治疗癫痫的临床疗效。方法选取2017年1月—2017年12月在解放军第452医院就诊的癫痫患者92例为研究对象,按照随机数字表法分为对照组和治疗组,每组各46例。对照组口服左乙拉西坦片,初始剂量0.5 g/次,2次/d,治疗2周后,剂量变为1.0 g/次,2次/d。治疗组在对照组治疗的基础上口服痫愈胶囊,5粒/次,2次/d。两组患者均连续治疗6个月。观察两组的临床疗效,比较两组的认知功能、神经递质水平和癫痫发作频率。结果治疗后,对照组和治疗组的总有效率分别为71.74%、82.61%,两组比较差异有统计学意义(P<0.05)。治疗后,两组注意、延迟回忆、定向、Mo CA评分均明显升高,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组认知功能指标明显高于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组神经胶质酸性蛋白(GFAP)、髓鞘碱性蛋白(MBP)水平均明显降低,脑源性神经营养因子(BDNF)水平明显升高,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组神经递质水平明显优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组发作频率明显降低,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组发作频率明显低于对照组,两组比较差异具有统计学意义(P<0.05)。结论痫愈胶囊联合左乙拉西坦片治疗癫痫具有较好的临床疗效,可改善认知功能,减少癫痫发作频率,调节神经递质水平,具有一定的临床推广应用价值。
Objective To investigate the clinical effect of Xianyu Capsules combined with Levetiracetam Tablets in treatment of epilepsy. Methods Patients(92 cases) with epilepsy in the 452 Hospital of People's Liberation Army from January 2017 to December 2017 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were po administered with Levetiracetam Tablets, starting dosage 0.5 g/time, twice daily, after 2 weeks, dosage changed 1.0 g/time, twice daily. Patients in the treatment group were po administered with Xianyu Capsules on the basis of the control group, 5 grains/time, twice daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacies were evaluated, and cognitive function, the frequency of epileptic seizures, and neurotransmitter levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 71.74% and 82.61%, respectively, and there was difference between two groups(P < 0.05). After treatment, the scores of attention, delayed recollection, orientation, and Mo CA in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And the cognitive function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of GFAP and MBP in two groups were significantly decreased, but the levels of BDNF in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And the neurotransmitter levels in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the frequencies of epileptic seizures in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the frequency of epileptic seizures in the treatment group was significantly lower than that in the control group, with significant difference between two groups(P < 0.05). Conclusion Xianyu Capsules combined with Levetiracetam Tablets has clinical curative effect in treatment of epilepsy, can improve cognitive function, reduce the frequency of epileptic seizures, regulate neurotransmitter, which has a certain clinical application value.
Objective To investigate the clinical effect of Xianyu Capsules combined with Levetiracetam Tablets in treatment of epilepsy. Methods Patients(92 cases) with epilepsy in the 452 Hospital of People's Liberation Army from January 2017 to December 2017 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were po administered with Levetiracetam Tablets, starting dosage 0.5 g/time, twice daily, after 2 weeks, dosage changed 1.0 g/time, twice daily. Patients in the treatment group were po administered with Xianyu Capsules on the basis of the control group, 5 grains/time, twice daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacies were evaluated, and cognitive function, the frequency of epileptic seizures, and neurotransmitter levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 71.74% and 82.61%, respectively, and there was difference between two groups(P < 0.05). After treatment, the scores of attention, delayed recollection, orientation, and Mo CA in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And the cognitive function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of GFAP and MBP in two groups were significantly decreased, but the levels of BDNF in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And the neurotransmitter levels in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the frequencies of epileptic seizures in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the frequency of epileptic seizures in the treatment group was significantly lower than that in the control group, with significant difference between two groups(P < 0.05). Conclusion Xianyu Capsules combined with Levetiracetam Tablets has clinical curative effect in treatment of epilepsy, can improve cognitive function, reduce the frequency of epileptic seizures, regulate neurotransmitter, which has a certain clinical application value.
引文
[1]涂雪松.癫痫的流行病学研究[J].脑与神经疾病杂志,2017,25(8):522-528.
[2]宋玉成,郭秀珍,王爱芹.左乙拉西坦对癫痫患者血清胶质纤维酸性蛋白水平、脑电活动及生活质量的影响[J].脑与神经疾病杂志,2017,25(1):11-14.
[3]张青,丁成赟,刘金民,等.322例癫痫患者中医体质分布特点研究[J].中华中医药杂志,2017,5(8):3801-3803.
[4]纪峰海,高阳.痫愈胶囊联合丙戊酸镁治疗癫痫的疗效观察[J].现代药物与临床,2018,33(4):750-753.
[5]劳动和社会保障部,中华医学会,中国抗癫痫协会.中国癫痫临床诊疗指南[M].北京:人民卫生出版社,2013:14.
[6]国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994:35-36.
[7]瞿治平.癫痫发作分类及药物临床疗效评定的建议(草案)[J].中国神经精神疾病杂志,1980,6(4):248.
[8]张立秀,刘雪琴.蒙特利尔认知评估量表中文版的信效度研究[J].护理研究,2007,21(11):2906-2907.
[9]苏绮璇,侯小兵.左乙拉西坦对癫痫患者血清细胞因子及认知状态相关指标的影响[J].海南医学,2017,28(22):3648-3651.
[10]王燕,程春娥,徐晓,等.左乙拉西坦治疗癫痫的效果及对认知功能的影响[J].国际精神病学杂志,2016,43(4):642-644.
[11]朱昊如,谢鸣.中医药防治癫痫的研究进展[J].中国药师,2017,20(9):1583-1588.
[12]谢强胜,宋协成,谢春红,等.痫愈胶囊质量标准研究[J].化学分析计量,2007,16(2):46-48.
[13]任鲜卉,申玉勤,康静,等.痫愈胶囊添加治疗癫痫的临床疗效和安全性观察[J].医学综述,2015,21(6):1102-1103.
[14]宋玉成,赵香莲.癫痫患者血清GFAP水平变化及其与认知功能的关系[J].山东医药,2015,55(45):91-92.
[15]郝伟红,姜红,马慧平,等.S100B蛋白、BDNF、IGF-1在癫痫婴儿血清中的水平及临床意义[J].中国临床研究,2017,30(9):1186-1188.
[16]杨小芳,喻明,聂本刚,等.单次癫痫发作后患者血清和脑脊液中神经元特异性烯醇化酶及髓鞘碱性蛋白的变化[J].华西医学,2010,25(11):2007-2008.
[17]危薇,徐志彬.69例癫痫患者MMSE与Mo CA评估的相关研究[J].海南医学,2012,23(2):29-31.
[2]宋玉成,郭秀珍,王爱芹.左乙拉西坦对癫痫患者血清胶质纤维酸性蛋白水平、脑电活动及生活质量的影响[J].脑与神经疾病杂志,2017,25(1):11-14.
[3]张青,丁成赟,刘金民,等.322例癫痫患者中医体质分布特点研究[J].中华中医药杂志,2017,5(8):3801-3803.
[4]纪峰海,高阳.痫愈胶囊联合丙戊酸镁治疗癫痫的疗效观察[J].现代药物与临床,2018,33(4):750-753.
[5]劳动和社会保障部,中华医学会,中国抗癫痫协会.中国癫痫临床诊疗指南[M].北京:人民卫生出版社,2013:14.
[6]国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994:35-36.
[7]瞿治平.癫痫发作分类及药物临床疗效评定的建议(草案)[J].中国神经精神疾病杂志,1980,6(4):248.
[8]张立秀,刘雪琴.蒙特利尔认知评估量表中文版的信效度研究[J].护理研究,2007,21(11):2906-2907.
[9]苏绮璇,侯小兵.左乙拉西坦对癫痫患者血清细胞因子及认知状态相关指标的影响[J].海南医学,2017,28(22):3648-3651.
[10]王燕,程春娥,徐晓,等.左乙拉西坦治疗癫痫的效果及对认知功能的影响[J].国际精神病学杂志,2016,43(4):642-644.
[11]朱昊如,谢鸣.中医药防治癫痫的研究进展[J].中国药师,2017,20(9):1583-1588.
[12]谢强胜,宋协成,谢春红,等.痫愈胶囊质量标准研究[J].化学分析计量,2007,16(2):46-48.
[13]任鲜卉,申玉勤,康静,等.痫愈胶囊添加治疗癫痫的临床疗效和安全性观察[J].医学综述,2015,21(6):1102-1103.
[14]宋玉成,赵香莲.癫痫患者血清GFAP水平变化及其与认知功能的关系[J].山东医药,2015,55(45):91-92.
[15]郝伟红,姜红,马慧平,等.S100B蛋白、BDNF、IGF-1在癫痫婴儿血清中的水平及临床意义[J].中国临床研究,2017,30(9):1186-1188.
[16]杨小芳,喻明,聂本刚,等.单次癫痫发作后患者血清和脑脊液中神经元特异性烯醇化酶及髓鞘碱性蛋白的变化[J].华西医学,2010,25(11):2007-2008.
[17]危薇,徐志彬.69例癫痫患者MMSE与Mo CA评估的相关研究[J].海南医学,2012,23(2):29-31.